Comparable M&A deals

Includes acquisitions of venture-backed biopharma companies since January 2018

Investor profiles: private investments
Investor profiles: public investments
Investor performance
Investor targeting
IPO comps
M&A comps

$ in millions


Target name Acquiror name Deal date Upfront value ($M) Total value ($M) Therapeutic areas Stage of lead asset

This is a preview of our platform. Subscribe for full access.